Table 2.
Treatment details (n = 228)
| Characteristics | No. of patients (%) |
|---|---|
| Radiotherapy | |
| 25 × 2Gy | 204 (89.5) |
| 5 × 5Gy | 24 (10.5) |
| First-line chemotherapy | |
| CAPOX | 180 (78.9) |
| CAPOX-B | 9 (3.9) |
| FOLFOX | 10 (4.4) |
| FOLFOX-B | 7 (3.1) |
| CAP | 15 (6.6) |
| CAP-B | 2 (0.9) |
| Other | 5 (2.2) |
| Time of chemotherapy (months) | |
| ≤ 3 | 23 (10.1) |
| 3–6 | 131 (57.5) |
| > 6 | 74 (32.5) |
| Rectal resection | n = 142 |
| Low anterior resection | 116 (81.7) |
| Abdominoperineal resection | 20 (14.1) |
| Hartmann procedure | 6 (4.2) |
| Diverting stoma | n = 73 |
| Simultaneous surgery | 50 (68.5) |
| During chemotherapy | 15 (20.5) |
| Before treatment | 8 (11.0) |
| pTRG (Mandard) a | n = 129 |
| Complete regression (TRG 1) | 25 (19.4) |
| Good regression (TRG 2) | 49 (38.0) |
| Moderate regression (TRG 3) | 41 (31.8) |
| Slight regression (TRG 4) | 14 (10.9) |
| Liver treatment | n = 85 |
| Liver resection | 30 (35.3) |
| RFA | 33 (38.8) |
| Resection + RFA | 18 (21.2) |
| Radiotherapy | 4 (4.7) |
| Treatment of extrahepatic metastases | |
| Lung | |
| RFA | 22 (9.6) |
| Metastasectomy | 7 (3.1) |
| Radiotherapy | 2 (0.9) |
| Lymph node resection | 6 (2.6) |
| Rectal radiotherapy expanded for lymph node | 28 (12.3) |
a pathological tumor regression grade of 5-tier Mandard adjuvant
Abbreviations: B bevacizumab, RFA radiofrequency ablation, CAP capecitabine, OX oxaliplatin; FOLFOX, 5-fluorouracil, folinic acid and oxaliplatin